Sign in

CIBMTR

@cibmtr.bsky.social
113 followers 43 following 116 posts

Research organization, collaborating with the global scientific community to increase survival and enrich quality of life for patients needing cellular therapy. Learn more at cibmtr.org.

PostsRepliesMedia
CIBMTR @cibmtr.bsky.social · 13h
Ready to connect with leaders across the field? #Tandem27 brings together experts in HCT, cellular therapy, and gene therapy for four days of education, collaboration, and networking. 📍 Orlando, FL 📅 Feb. 17-20, 2027 Register: www.tandemmeetings.com/Registration...
000
CIBMTR @cibmtr.bsky.social · 29/09/2026
NEW: CIBMTR Research Haploidentical versus HLA-matched unrelated donors for HCT in acute leukemia Read more: 🔗 pubmed.ncbi.nlm.nih.gov/42323086/
000
CIBMTR @cibmtr.bsky.social · 25/09/2026
The future of HCT, cellular therapy, and gene therapy starts at #Tandem27. Join experts, researchers, and clinicians as they share the latest advances shaping patient care. 📍 Orlando, FL | 📅 Feb. 17-20, 2027 Register: www.tandemmeetings.com/Registration...
000
CIBMTR @cibmtr.bsky.social · 25/09/2026
Abstract submission for #Tandem27 is now open! ASTCT and CIBMTR invite you to share your research with your HCT, cell, and gene therapy colleagues in Orlando, FL, February 17-20, 2027! Learn more: www.tandemmeetings.com/Abstracts/Ab... @astct.bsky.social
000
CIBMTR @cibmtr.bsky.social · 24/09/2026
NEW: CIBMTR Research Access challenges in alloHCT: Identifying at-risk US states by exploring social vulnerability, physician density, and unmet need Read more: 🔗pubmed.ncbi.nlm.nih.gov/42372215/
000
CIBMTR @cibmtr.bsky.social · 24/09/2026
NOW AVAILABLE: 2014-2024 Non-Malignant Summary Slides. These slides detail the clinical practices, trends, and survival outcomes following HCT and cellular therapy, including gene therapy for non-malignant diseases. Learn more: cibmtr.org/CIBMTR/Resou...
000
CIBMTR @cibmtr.bsky.social · 22/09/2026
NEW: CIBMTR Research Classical HLA allele and haplotype frequency estimates in US populations Read more: 🔗 pubmed.ncbi.nlm.nih.gov/42341485/
010
CIBMTR @cibmtr.bsky.social · 17/09/2026
NEW: CIBMTR Research Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report Read more: 🔗pubmed.ncbi.nlm.nih.gov/42416786/
000
CIBMTR @cibmtr.bsky.social · 16/09/2026
The wait is over. Registration for #Tandem27 is officially open! Join ASTCT and CIBMTR in Orlando, February 17-20, 2027, for the premier event in HCT, cellular therapy, and gene therapy. 📍 Orlando, FL 📅 February 17-20, 2027 Secure your spot today: www.tandemmeetings.com/Registration...
000
CIBMTR @cibmtr.bsky.social · 16/09/2026
Could your research question change practice? Don't miss your chance to shape future research. There's only 1 week left to submit a proposal for consideration for a CIBMTR Working Committee study. 📅 Deadline: Monday, Sept. 21 🔗cibmtr.org/CIBMTR/Resea...
000
CIBMTR @cibmtr.bsky.social · 10/09/2026
NEW: CIBMTR Research Infection burden in mismatched unrelated donor HCT: Results from the ACCESS Trial Read more: 🔗pubmed.ncbi.nlm.nih.gov/42448319/
000
CIBMTR @cibmtr.bsky.social · 09/09/2026
💡 Your next research idea could help shape the future of transplantation and cellular therapy. CIBMTR is accepting Working Committee Study proposals from investigators interested in leading impactful observational research. 📅 Deadline: Monday, Sept. 21 Submit today: cibmtr.org/CIBMTR/Resea...
000
CIBMTR @cibmtr.bsky.social · 03/09/2026
Visit our Study Summaries page to find what you need—clinical trials and trusted education tools, all in one place. New summaries are added regularly! Explore: cibmtr.org/summaries
000
CIBMTR @cibmtr.bsky.social · 03/09/2026
Have a research question that could advance the field of cellular therapy? Submit a CIBMTR Working Committee study proposal for consideration at the 2027 Tandem Meetings. 📅 Deadline: Monday, Sept. 21 🔗 cibmtr.org/CIBMTR/Resea...
000
CIBMTR @cibmtr.bsky.social · 02/09/2026
Abstract submission for #Tandem27 is now open! ASTCT and CIBMTR invite you to share your research with your HCT, cell, and gene therapy colleagues in Orlando, FL, February 17-20, 2027! Learn more www.tandemmeetings.com/Abstr.../Abs... @astct.bsky.social
000
CIBMTR @cibmtr.bsky.social · 01/09/2026
NEW: BMT CTN Research CD8+CD38+ T cells identify functional high-risk multiple myeloma after autologous transplant: BTM CTN 0702 correlates Read more: 🔗 ashpublications.org/bloodneoplas...
000
CIBMTR @cibmtr.bsky.social · 27/08/2026
NEW: BMT CTN Research TITE-safety: A robust time-to-event safety monitoring approach for clinical trials Read more: 🔗pubmed.ncbi.nlm.nih.gov/42201841/
000
CIBMTR @cibmtr.bsky.social · 25/08/2026
NEW: BMT CTN Research Commensurate prior models with random effects for interval-censored data to accommodate historical controls Read more: 🔗www.tandfonline.com/doi/full/10....
000
CIBMTR @cibmtr.bsky.social · 21/08/2026
Abstract submission for #Tandem27 is now open! ASTCT and CIBMTR invite you to share your research with your HCT, cell, and gene therapy colleagues in Orlando, FL, February 17-20, 2027! Learn more www.tandemmeetings.com/Abstr.../Abs... @astct.bsky.social
000
CIBMTR @cibmtr.bsky.social · 20/08/2026
NEW: CIBMTR Research Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in AML in first complete remission: CIBMTR analysis Read more: 🔗pubmed.ncbi.nlm.nih.gov/42206435/
000
CIBMTR @cibmtr.bsky.social · 18/08/2026
Clear, simple research—our Study Summaries break down complex topics into easy-to-understand insights, helping patients feel informed and confident. Explore: cibmtr.org/summaries
010
CIBMTR @cibmtr.bsky.social · 18/08/2026
Clinical trial for mismatched transplant helps more people. Read about this CIBMTR study to learn more: cibmtr.org/Patient-Summ...
000
CIBMTR @cibmtr.bsky.social · 13/08/2026
NEW: CIBMTR Research IMPACT for patients with inborn errors of immunity from the Primary Immune Deficiency Treatment Consortium Read more: 🔗pubmed.ncbi.nlm.nih.gov/42242424/
000
CIBMTR @cibmtr.bsky.social · 11/08/2026
Staying up to date is simple. Sort Study Summaries by date to see the latest findings and newly added studies. Explore what’s new: cibmtr.org/summaries
000
CIBMTR @cibmtr.bsky.social · 06/08/2026
NEW: CIBMTR Research Comparison of fludarabine versus bendamustine as a lymphodepleting chemotherapy prior to CAR T for large cell lymphoma Read more: 🔗pubmed.ncbi.nlm.nih.gov/42341926/
000
CIBMTR @cibmtr.bsky.social · 05/08/2026
CIBMTR and the MCW Division of Hematology and Oncology invite applications for a faculty position as a CIBMTR Senior Scientific Director. Learn more about and apply for this important position: mcw.wd503.myworkdayjobs.com/en-US/Extern...
001
CIBMTR @cibmtr.bsky.social · 04/08/2026
Take a look—filter our Study Summaries by disease or condition. Quickly explore plain-language info on lymphoma, multiple myeloma, sickle cell disease, and more: cibmtr.org/summaries
000
CIBMTR @cibmtr.bsky.social · 04/08/2026
🔬 What's new at CIBMTR? The August 2026 Newsletter is here! Explore research highlights from our working committees, updates on adoptive cellular therapies & gene therapy reporting, 2025 US Summary Slides, and a preview of #Tandem27. 📬 cibmtr.org/CIBMTR/About...
000
CIBMTR @cibmtr.bsky.social · 30/07/2026
NEW: CIBMTR Research Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR analysis Read more: 🔗pubmed.ncbi.nlm.nih.gov/42364732/
000
CIBMTR @cibmtr.bsky.social · 28/07/2026
It’s easy to explore our Study Summaries page. Browse by category and quickly find plain-language research summaries—in a clear, user-friendly format. Check it out: cibmtr.org/summaries
000
CIBMTR @cibmtr.bsky.social · 22/07/2026
NEW: CIBMTR Research Quantile regression of the relationship between demographic factors and leukocyte telomere length, measured by Southern blot and qPCR Read more: 🔗pubmed.ncbi.nlm.nih.gov/41619133/
000
CIBMTR @cibmtr.bsky.social · 20/07/2026
NEW: CIBMTR Research Recommendations for HLA genotyping data standards and clinical laboratory staffing considerations Read more: 🔗 pubmed.ncbi.nlm.nih.gov/42007733/
000
CIBMTR @cibmtr.bsky.social · 17/07/2026
Need more transplant resources? Our Study Summaries page now links to clinical trial summaries and education tools to support every step of the journey. Explore more ➡️ cibmtr.org/summaries
010
CIBMTR @cibmtr.bsky.social · 13/07/2026
NEW: BMT CTN Research Antigen-specific T cell responses to SARS-CoV-2 vaccination after HCT or CAR T-cell therapy Read more: 🔗pubmed.ncbi.nlm.nih.gov/41941698/
010
CIBMTR @cibmtr.bsky.social · 09/07/2026
NEW: CIBMTR Research Patients with MDS/MPN have higher rates of relapse following allogeneic HCT compared to those with MDS: A Brazilian SBTMO/CIBMTR registry analysis Read more: 🔗pubmed.ncbi.nlm.nih.gov/42032308/
000
CIBMTR @cibmtr.bsky.social · 07/07/2026
NEW: CIBMTR Research Optimal donor selection for transplant to reduce GVHD risk and augment graft-versus-malignancy efficacy Read more: 🔗pubmed.ncbi.nlm.nih.gov/42060959/
000
CIBMTR @cibmtr.bsky.social · 01/07/2026
NEW: CIBMTR Research Factors associated with receipt of allogeneic HCT and NMDP donor search in older adults with AML Read more: 🔗pubmed.ncbi.nlm.nih.gov/42069181/
000
CIBMTR @cibmtr.bsky.social · 30/06/2026
CIBMTR Research HCT access and patient diversity Read more: 🔗pubmed.ncbi.nlm.nih.gov/42084866/
000
CIBMTR @cibmtr.bsky.social · 26/06/2026
NEW: CIBMTR Research Donor source selection in HCT: Practices and perceptions across 50 U.S. transplant centers Read more: 🔗pubmed.ncbi.nlm.nih.gov/42086170/
000
CIBMTR @cibmtr.bsky.social · 24/06/2026
NEW: CIBMTR Research Outcomes of HCT in patients with plasmablastic lymphoma Read more: 🔗 pubmed.ncbi.nlm.nih.gov/42173253/
010
CIBMTR @cibmtr.bsky.social · 19/06/2026
Guiding a patient through transplant prep? Our Study Summaries turn complex research into clear, easy‑to‑read explanations—helping patients stay informed and confident. Start exploring ➡️cibmtr.org/summaries
000
CIBMTR @cibmtr.bsky.social · 17/06/2026
NOW AVAILABLE: 2025 CIBMTR Summary Slides. These slides provide an annual report on data submitted by US centers to CIBMTR, detailing practices and general survival outcomes following cellular therapies. Learn more: cibmtr.org/CIBMTR/Resou...
010
CIBMTR @cibmtr.bsky.social · 11/06/2026
Children who donate blood or marrow need more support. Read about this CIBMTR study to learn more: cibmtr.org/Patient-Summ...
000
CIBMTR @cibmtr.bsky.social · 10/06/2026
Sibling donors reduce chances of graft-versus-host disease. Read about this CIBMTR study to learn more: cibmtr.org/Patient-Summ...
000
CIBMTR @cibmtr.bsky.social · 08/06/2026
Kids who have transplant may have fertility problems later. Read about this CIBMTR study to learn more: cibmtr.org/Patient-Summ...
000
CIBMTR @cibmtr.bsky.social · 05/06/2026
New tool predicts risk of long-term effects after transplant. Read about this CIBMTR study to learn more: cibmtr.org/Patient-Summ...
010
CIBMTR @cibmtr.bsky.social · 15/05/2026
Want the newest transplant research at your fingertips? You can now sort our Study Summaries by date—making it simple to track recent findings and stay informed as new studies roll out. Take a look ➡️ cibmtr.org/summaries
000
CIBMTR @cibmtr.bsky.social · 14/05/2026
🚨 New for 2026! 🚨 After #Tandem26, CIBMTR is proud to share the accepted Working Committee studies—advancing innovation in cellular therapy & transplantation. See the full list: 🔗 cibmtr.org/Files/2026-N... #CIBMTR #CellTherapy #BMT #Research
000
CIBMTR @cibmtr.bsky.social · 17/04/2026
Trustworthy transplant research—now easier to find. Explore Study Summaries organized by disease and condition: lymphoma, multiple myeloma, sickle cell disease, and more. Start exploring ➡️cibmtr.org/summaries
000
CIBMTR @cibmtr.bsky.social · 27/03/2026
Our study summaries page just got a major upgrade! Search by category, find what you need faster, and browse clear, plain‑language summaries. Explore the new layout ➡️ cibmtr.org/summaries
000